Akero Therapeutics, Inc. - Common Stock (NQ:AKRO)

54.74 UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 8, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Akero Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

August 28, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH

August 14, 2025

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH

From Akero Therapeutics Inc.

Via GlobeNewswire

Akero Therapeutics Inc (NASDAQ:AKRO) Reports Q2 2025 Earnings: Narrower Loss and Clinical Progress Drive Investor Optimism ↗

August 08, 2025

Akero Therapeutics reports Q2 2025 results with narrower-than-expected loss, strong cash reserves, and promising clinical progress in MASH treatment. Stock gains 6.5% pre-market.

Via Chartmill

This Stock Just Doubled in 1 Day -- Is It Still a Buy? ↗

February 02, 2025

Via The Motley Fool

Akero (AKRO) Q2 Loss Narrows 6% ↗

August 08, 2025

Via The Motley Fool

Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 08, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

August 04, 2025

Via Benzinga

AKERO THERAPEUTICS INC (NASDAQ:AKRO) - A Strong Technical Setup in Biotech ↗

July 18, 2025

AKERO THERAPEUTICS (NASDAQ:AKRO) shows strong technicals with a perfect 10 rating and a high-quality breakout setup, making it a stock to watch for traders.

Via Chartmill

Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased ↗

June 13, 2025

Jefferies thinks big pharma companies are "still on the hunt" for deals.

Via Stocktwits

Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

June 03, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

May 28, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Akero Therapeutics Stock Rallies To 3-Month High On Buyout Report; Retail Investors Turn Bullish ↗

May 20, 2025

The company reportedly hired an investment bank to explore a possible sale.

Via Stocktwits

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 20, 2025

Via Benzinga

Best Biotech Stocks to Buy in 2025

May 13, 2025

Discover the best biotech stocks of 2025, including top performers like Vertex and Regeneron, driven by clinical breakthroughs and strong investor momentum.

Via MarketBeat

Topics ETFs Economy Government

Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

May 10, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine

May 09, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025

May 09, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference

May 07, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Long-Term Shareholders Have Rights – If You Hold Akero Therapeutics, Inc. (NASDAQ: AKRO); Integra Lifesciences Holdings Corporation (NASDAQ: IART); Mercury Systems, Inc. (NASDAQ: MRCY); or Virtu Financial Inc. (NASDAQ: VIRT), Contact Grabar Law Office

May 05, 2025

From Grabar Law Office

Via GlobeNewswire

Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025

April 30, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

April 01, 2025

Via Benzinga

Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is

March 24, 2025

From Grabar Law Office

Via GlobeNewswire

The Stock Market Hates Uncertainty & Loves To Climb A Wall-Of-Worry ↗

March 21, 2025

In this video lesson, I review the overall market and a new swing position for Monday's session.

Via Talk Markets

Topics ETFs Stocks / Equities

10 Health Care Stocks Whale Activity In Today's Session ↗

March 21, 2025

Via Benzinga

3 Mid-Caps Worth Watching Closely in March

February 28, 2025

Unlike their mega-cap counterparts, which tend to grind, mid-caps can soar or crash within days, driven by headlines and pure speculation.

Via MarketBeat

Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

February 28, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Akero Therapeutics, Inc. (NASDAQ: AKRO); Crocs, Inc. (NASDAQ: CROX); Extreme Networks, Inc. (NASDAQ: EXTR); and Domino’s Pizza Corp. (NASDAQ: DPZ)

February 20, 2025

From Grabar Law Office

Via GlobeNewswire

Akero Therapeutics, Brinker International And Viavi Are Among Top Mid Cap Gainers Last Week (Jan 27-Jan 31): Are The Others In Your Portfolio? ↗

February 02, 2025

Check out this week's top-performing mid-cap stocks, including Akero Therapeutics' remarkable 106.57% surge following positive clinical trial results and other companies like Surgery Partners...

Via Benzinga

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

January 30, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.